Please login to the form below
Replagal
This page shows the latest Replagal news and features for those working in and with pharma, biotech and healthcare.
Amicus gets NICE green light for Fabry drug
Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal
Latest news
-
NICE backs Amicus Therapeutics’ Galafold
and Shire's Replagal (agalsidase alfa).
-
GSK gene therapy tops CHMP recommendations
The drug could offer a patient-friendly alternative to injectable Fabry therapies such as Sanofi/Genzyme's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).
-
Sanofi gains accelerated review for rare disease drug
But even though catering for a small patient population (around 10, 000 people are thought to have the disorder globally), the firm has competition in Shire's Replagal (agalsidase alfa).
-
AbbVie coaxes Shire into discussions with sweetened offer
as Elaprase (idursulfase) for Hunter syndrome and Replagal (agalsidase alfa) for Fabry disease.
-
The moving parts of orphan drug development
The company already had its own orphan brands such as Replagal (agalsidase alfa) for Fabry disease, Hunter's syndrome treatment Elaprase (idursulfase) and Vpriv (velaglucerase alfa) for Gaucher disease, when it
More from news
Approximately 2 fully matching, plus 15 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
-
Senior Medical Writer
-
Competitive salary plus benefits
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
-
Senior Copywriter
-
Salary TBC
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
Subscribe to our email news alerts
- Novartis bags US okay for Lucentis follow-up Beovu in wet AMD
- GSK forms cell therapy R&D pact with star-studded biotech
- UCB gets bigger in rare diseases with $2.1bn purchase of Ra Pharma
- Merck seeks partner for disease-modifying osteoarthritis drug
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Alexion eyes Soliris combo with $930m deal to buy Achillion
- The Golden Goose
- What is changing in cardiovascular disease care?
- Tranexamic acid linked to lower death rate in some brain injury patients
- Horizon shares data on eye disease drug as FDA decision nears
- Allergan investors back AbbVie deal, but is a tax charge looming?
PMHub
Attigo (part of the Mednet Group)
Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...
Latest intelligence
- The Golden Goose
- Why it’s so hard for the US to curb runaway drug prices...
- What is changing in cardiovascular disease care?
- Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
- PANDAS/PANS Awareness: A parent’s story
- To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Quick links
Infographics
